Intravitreal Combination of Dexamethasone Sodium Phosphate and Bevacizumab in The Treatment of Exudative AMD

被引:0
|
作者
N. Vakalis
G. Echiadis
A. Pervena
I. Deligiannis
E. Kavalarakis
S. Giannikakis
I. Papaefthymiou
机构
[1] Consultant in ophthalmology,Department of Ophthalmology
[2] Naval Hospital of Athens,Department of Ophthalmology
[3] Resident in ophthalmology,Head of Department of Ophthalmology
[4] Naval Hospital of Athens,undefined
[5] Consultant in ophthalmology,undefined
[6] Naval Hospital of Athens,undefined
来源
Scientific Reports | / 5卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of this study is to investigate the efficacy and safety of intravitreal dexamethasone sodium phosphate (DSP) combined with bevacizumab for the treatment of neovascular age-related macular degeneration (AMD). In this non comparative case study, 30 eyes of 27 patients with CNV due to AMD received intravitreal DSP (0.2 mg) and bevacizumab (1.25 mg) during a 6-month PRN (pro re nata) dosing regimen. Visual acuity, macular thickness and intraocular pressure (IOP) were monitored and recorded. After 6 months, mean retinal thickness decreased from 423.5 ± 75.3 to 228.2 ± 34.5 and mean visual acuity improved from 0.9 ± 0.39 logMAR to 0.53 ± 0.34 (p = 0.001) logMAR. During the trial period, 81 intravitreal injections were performed in 30 eyes, thus the mean number of injections per eye was 2.7 ± 1.1. 86.7% of the eyes required 3 or less injections while only 13.3% needed 4 or more injections. None of the patients, phakic or pseudophakic, manifested an elevation of IOP during the treatment, ranging between 12 and 22 mmHg. Combined DSP and bevacizumab offers encouraging results in the challenge of AMD treatment, providing immediate response of macular edema, reduced number of intravitreal injections and stabilization or improvement of visual acuity.
引用
收藏
相关论文
共 50 条
  • [31] Electrophysiological effects of intravitreal Avastin (bevacizumab) in the treatment of exudative age-related macular degeneration
    Karanjia, R.
    Eng, K. T.
    Gale, J.
    Sharma, S.
    ten Hove, M. W.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2008, 92 (09) : 1248 - 1252
  • [32] INTRAVITREAL BEVACIZUMAB TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH GOOD VISUAL ACUITY
    Axer-Siegel, Ruth
    Bor, Elite
    Bourla, Dan H.
    Weinberger, Dov
    Mimouni, Karin
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2012, 32 (09): : 1811 - 1820
  • [33] Combination Therapy with Bevacizumab and Dexamethasone Intravitreal Implant vs Dexamethasone Implant Alone in Patients with Retinal Vein Occlusion (RVO)
    Mishra, Sanjay
    Gupta, Abhishek
    Parihar, Jitender Singh
    OPHTHALMOLOGICA, 2014, 232 : 88 - 89
  • [34] Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration
    Bidot, M. L.
    Malvitte, L.
    Bidot, S.
    Bron, A.
    Creuzot-Garcher, C.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2011, 34 (06): : 376 - 381
  • [35] Intravitreal dexamethasone implant for acute exudative polymorphous vitelliform maculopathy
    Scupola, Andrea
    Abed, Edoardo
    Sammarco, Maria Grazia
    Traina, Salvatore
    Villano, Antonio
    Grimaldi, Gabriela
    Blasi, Maria Antonietta
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2014, 24 (05) : 803 - 807
  • [36] Short-term Results of Intravitreal Dexamethasone Implant Combined with Bevacizumab versus Intravitreal Bevacizumab for Treatment-naive Diabetic Macular Edema
    Lee, Yeo Jin
    Kang, Kui Dong
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2020, 61 (12): : 1485 - 1492
  • [37] Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD
    Schaal, K. B.
    Engler, C.
    Schuett, F.
    Scheuerle, A.
    Dithmar, S.
    OPHTHALMOLOGE, 2008, 105 (06): : 538 - +
  • [38] Intravitreal Aflibercept in Eyes with Neovascular AMD Requiring Frequent Retreatment with Intravitreal Bevacizumab or Ranibizumab
    Thorell, Mariana Rossi
    Nunes, Renata Portella
    Gregori, Giovanni
    Feuer, William J.
    Rosenfeld, Philip J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [39] RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD
    Maria Andreea Gamulescu
    Carsten Framme
    Helmut Sachs
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2006, 245 : 1037 - 1040
  • [40] RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD
    Gamulescu, Maria Andreea
    Framme, Carsten
    Sachs, Helmut
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2007, 245 (07) : 1037 - 1040